You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

CLINICAL TRIALS PROFILE FOR NELARABINE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nelarabine

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003545 ↗	506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Completed	Southwest Oncology Group	Phase 2	1998-08-01	Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
NCT00003545 ↗	506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1998-08-01	Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
NCT00003635 ↗	506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents	Completed	National Cancer Institute (NCI)	Phase 2	1999-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents.
NCT00003635 ↗	506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents	Completed	GlaxoSmithKline	Phase 2	1999-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Nelarabine

Condition Name

Chart
Table

Condition Name for Nelarabine
Intervention	Trials
Leukemia	7
Lymphoblastic Lymphoma	4
Acute Lymphoblastic Leukemia	4
T Acute Lymphoblastic Leukemia	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Nelarabine
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	20
Leukemia, Lymphoid	19
Leukemia	19
Lymphoma	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Nelarabine

Trials by Country

Map
Table

Trials by Country for Nelarabine
Location	Trials
United States	176
Germany	12
Canada	12
Australia	8
France	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Nelarabine
Location	Trials
Texas	13
California	11
Ohio	8
Illinois	7
New York	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Nelarabine

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Nelarabine
Clinical Trial Phase	Trials
Phase 3	5
Phase 2/Phase 3	1
Phase 2	12
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Nelarabine
Clinical Trial Phase	Trials
Completed	12
Recruiting	9
Terminated	4
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nelarabine

Sponsor Name

Chart
Table

Sponsor Name for Nelarabine
Sponsor	Trials
National Cancer Institute (NCI)	13
GlaxoSmithKline	6
M.D. Anderson Cancer Center	3
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Nelarabine
Sponsor	Trials
Other	43
Industry	20
NIH	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.